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doi:10.1016/j.jtcvs.2006.03.058ackground: Although video-assisted thoracic surgery (VATS) has been in use for
ore than a decade, its application to major lung resection for lung cancer is still not
idely practiced. The success of a cancer operation is judged by the long-term
urvival of the treated patients. Therefore, the goal of the present study was to
valuate long-term outcomes associated with various video-assisted lobectomy
echniques and conventional surgery in patients with peripheral non–small cell lung
ancer less than or equal to 2 cm in diameter (stage IA).
ethods: A multi-institutional, retrospective review was performed in 145 consec-
tive patients. Patients with clinical stage IA disease, with tumor size less than or
qual to 2 cm in diameter, from three institutions underwent a complete VATS
c-VATS, n  56), an assisted VATS (a-VATS, n  34), or a conventional open
open, n  55) approach for pulmonary lobectomy and lymph node dissection.
esults: Patients undergoing lobectomy and lymph node dissection with c-VATS
ad less blood loss, faster recovery, shorter hospitalization, and longer operating
imes than did patients undergoing the lobectomy with the a-VATS and open
pproaches. At a mean follow-up of 38.8 months, Kaplan-Meier probabilities of
urvival at 5 years were as follows: c-VATS, 96.7%; a-VATS, 95.2%; open, 97.2%.
here was no significant difference in the rate of recurrence among the 3 different
rocedures.
onclusion: VATS lobectomy, a safe procedure with earlier return to normal
ctivities, can be regarded as an acceptable cancer operation for the patients with
eripheral non–small cell lung cancer less than or equal to 2 cm in diameter (clinical
tage IA) with the same long-term survivals as open surgery.
lthough video-assisted thoracoscopic (VATS) lobectomy with hilar and
mediastinal lymph node dissection has been used for more than a decade in
the management of patients with lung cancer,1,2 this technique is still not
idely practiced.3,4 Many surgeons have expressed concerns about the adequacy of
ATS lobectomy as a cancer operation. An early, small, multi-institutional ran-
omized study of lobectomy failed to demonstrate any benefit of VATS over
horacotomy.5 However, one problem with this type of study is that the VATS
obectomy procedures include a broad spectrum of operative techniques that range
rom complete endoscopic surgery to minithoracotomy with a thoracoscope serving
nly as a light source.6 This variability in VATS techniques may contribute to
onfusion regarding the benefits of VATS lobectomy for management of lung
ancer. Indeed, we7 previously demonstrated that different VATS lobectomy tech-
iques yielded different perioperative outcomes. Nonetheless, enough evidence to
uggest that VATS lobectomy as a treatment for lung cancer is not compromised in
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TSerms of long-term benefits has yet to be proven, because the
uccess of a cancer treatment is judged only by the long-
erm survival of the treated patients.
Therefore, the goal of the present study was to evaluate
ong-term outcomes of various VATS lobectomy techniques
nd conventional surgery in patients with clinical stage IA
ung cancer.
aterials and Methods
retrospective review of 145 consecutive patients with clinical
tage IA non–small cell lung cancer (NSCLC) less than or equal to
cm in diameter undergoing VATS and conventional thoracotomy
or lobectomy and systematic nodal dissection was conducted at
hree centers from January 1999 and January 2004.
All patients underwent noninvasive staging with thoracic, up-
er abdominal, and brain computed tomography (CT) to verify
bsence of multiple pulmonary lesions and hepatic, adrenal, or
rain metastases. Supplementary hepatic ultrasound and bone scin-
igraphic scans were ordered when clinically indicated. Standard
riteria including adequate functional status and pulmonary re-
erve were uniformly used to identify operative candidates at all
Abbreviations and Acronyms
ACT  Active Tracer AC-301
a-VATS assisted video-assisted thoracic surgery
CI  confidence index
CT  computed tomography
c-VATS complete video-assisted thoracic surgery
NSCLC  non–small cell lung cancer
VATS  video-assisted thoracic (thoracoscopic)
surgery08 The Journal of Thoracic and Cardiovascular Surgery ● Septetudy sites. Patients were included in the study only if their
reoperative CT scans showed the primary tumor to be amenable
o complete VATS (c-VATS) resection according to predeter-
ined criteria. These criteria included stage IA disease on CT,
rimary tumor smaller than 2 cm in long-axis diameter, tumor
ituated at least 2 cm from hilar vessels or interlobar fissures, no
istory of previous thoracic surgery or pleurodesis, and preopera-
ive pulmonary function tests suggesting ability to tolerate one-
ung ventilation. These criteria were agreed on by the senior
urgeons from all participating centers before this study. Once
ach patient had been selected as a potential candidate for
-VATS, the surgical approach used was decided by the preference
f the surgeon.
The technical aspects of VATS lobectomy were described
reviously.7 In brief, c-VATS used purely endoscopic techniques
ith 100% monitor vision without rib-spreading minithoracotomy,
hereas assisted VATS (a-VATS) involved performing the main
rocedures via rib spreading and used minithoracotomy (10 cm
ong) with monitor and direct vision. The open method (open) was
erformed via thoracotomy (20 cm long) with direct vision only.
he differences among the 3 approaches are illustrated in Figure 1.
systematic nodal dissection was performed in all cases, and
hen VATS techniques were applied, the procedures were iden-
ical to those used with thoracotomy. Nine patients required con-
ersion of the intended procedure to an alternate procedure
c-VATS to a-VATS, n  4; c-VATS to open, n  2; a-VATS to
pen, n  3) secondary to adhesions surrounding the pulmonary
rteries (n  3), stapler malfunction (n  2), severe intrathoracic
dhesions (n  2), or failure of lung collapse (n  2). These cases
ere excluded from analysis.
Regarding the postoperative pain control, patients in all 3
roups were offered the same analgesic regimens and all patients
ere studied with a similar degree of pain. Otherwise, common
rotocols were also used for postoperative management at all study
Figure 1. Descriptions of 3 differ-
ent approaches for pulmonary lo-
bectomy with systematic lymph
node dissection. A, Complete VATS
lobectomy (c-VATS): 3 ports and
a window (4 cm in length to be
used as the utility thoracotomy)
were made. Standard commer-
cially available endoscopic surgi-
cal tools were used, and all oper-
ative work was performed under
thoracoscopy. B, Assisted VATS
lobectomy (a-VATS): major manip-
ulation, including dissection of
the mediastinal lymph nodes, was
performed with video assistance
and under direct vision via a
10-cm long minithoracotomy. C,
Open conventional thoracotomy
(open): all procedures were per-
formed under direct vision via a
20-cm-long thoracotomy.
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G
TSites. An accelerometer (Active Tracer AC-301 [ACT]; GMS Inc,
okyo, Japan) was used for measurement of postoperative physical
ctivity, as previously described.8 In brief, the ACT is a device that
ontinuously measures the gravitational acceleration of body
ovement using built-in acceleration sensors and hence permits a
uantitative evaluation of integrative physical activity. The data
ere collected in consecutive preoperative 24-hour periods up to
ostoperative day 7, and these postoperative values were expressed
s a percentage of the preoperative value. Then, we called a
arameter recovery time, defined as the number of days required
or restoration to more than 90% of the preoperative value, to
ssess the duration of recovery quantitatively.
All data are expressed as mean  standard error. Statistical
nalysis was performed with StatView version 5 (SAS Institute,
nc, Cary, NC). Continuous and categorical variables were ana-
yzed with the Student t test and Fisher exact test, respectively.
ostoperative survival was plotted according to the Kaplan-Meier
ethod, and any difference in survival between the groups was
valuated with the log-rank test.
esults
atient characteristics are summarized in Table 1. There
as no significant difference in age, gender distribution,
ulmonary function, histology, or tumor distribution when
omparing the 3 study groups. Complete follow-up was
btained in all patients, and none of the patients received
djuvant or neoadjuvant treatment.
Operative time was longer for c-VATS (246  47 min-
ABLE 1. Patient characteristics
c-VATS a-VATS Open
ale/female 26/24 14/17 29/26
ge (y) 66 10 64  11 62  9
EV1.0 (L) 2.28 0.65 2.32 0.58 2.45 0.93
EV1.0 (%) 72.6 9.8 74.9 7.6 76.0  8.8
istology
Adenocarcinoma 34 26 38
Squamous cell
carcinoma
8 2 6
Bronchioloalveolar
carcinoma
5 3 7
Adenosquamous
carcinoma
1 0 1
Large cell
carcinoma
2 0 3
obectomy site
RUL 16 10 17
RML 5 2 3
RLL 11 7 12
LUL 11 8 16
LLL 7 4 7
otal 50 31 55
EV1.0 , Forced expiratory volume in 1 second; RUL, right upper lobe; RML,
ight middle lobe; RLL, right lower lobe; LUL, left upper lobe; LLL, left lower
obe.tes) than for a-VATS (169  27 minutes) or open surgery d
The Journal of Thoracic159  28 minutes) (P  .05; c-VATS vs other approach)
Figure 2, A). Estimated blood loss was lower for c-VATS
96  65 mL) than for other approaches (Figure 2, B), and
assive bleeding (eg, 500 mL of blood loss or need for
ntraoperative transfusions) did not occur in any case. In all
atients with a preoperative diagnosis of clinical stage I
isease, there was no significant difference in the number of
igure 2. Operative outcomes after pulmonary lobectomy and
ystematic lymph node dissection by c-VATS, a-VATS, and open
pproach. A, Operative time. B, Blood loss. C, Number of lymph
odes dissected during surgery. c-VATS, Complete video-assisted
horacoscopic surgery (VATS) lobectomy; a-VATS, assisted VATS
obectomy; open, open conventional thoracotomy; NS, not signif-
cant. Values are mean  standard deviation.issected lymph nodes (Figure 2, C). Recovery time ana-
and Cardiovascular Surgery ● Volume 132, Number 3 509
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TSyzed by ACT was shorter in patients undergoing c-VATS
han in patients undergoing a-VATS or open surgery ( p 
.05) (Figure 3). There was no postoperative mortality.
omplications (Table 2) were recorded in fewer than 3
atients in each group, but there was no significant dif-
erence in complication rate when comparing the 3
roups. Median length of hospitalization was shorter for
atients undergoing c-VATS (11.8  2.7 days) than for pa-
ients undergoing a-VATS and open procedures (P  .05)
Figure 4).
igure 3. Comparison of the postoperative physical ability as
etermined by Active Tracer and expressed as the percentage of
he preoperative 24-hour value. Time points included are before
urgery and 0, 1, 2, 3, 4, 5, and 6 days postoperatively. Each value
epresents the mean standard error at each time point. *P< .05
or complete VATS (c-VATS) versus assisted VATS (a-VATS).
ABLE 2. Complications after the operation
Complication No. of cases
c-VATS (50 cases)
Prolonged air leak 1
Chylothorax 1
Arrhythmia 1
Total 3/50 (6%)
a-VATS (31 cases)
Prolonged air leak 1
Arrhythmia 1
Total 2/31 (6%)
Open (55 cases)
Prolonged air leak 1
Pneumonia 1
Liver dysfunction 1
Total 3/55 (5%)
-VATS, Complete video-assisted thoracic surgery; a-VATS, assisted video-
(ssisted thoracic surgery.
10 The Journal of Thoracic and Cardiovascular Surgery ● SepteOn the basis of pathologic evaluation, upstaging was
oted in 8 of 136 (5.9%). These patients were included in
oth the survival and recurrence analyses. Mean follow-up
as 38.8 months (range, 10 months to 5 years), and there
as no significant difference in follow-up time when com-
aring the 3 groups. The overall 5-year survival was 96.4%
% (Figure 5). Of the deaths to date, only 1 death was related
o lung cancer. Four patients are alive with recurrent disease
t 13 to 36 months after resection (Table 3). Kaplan-Meier
urvival at 5 years for peripheral small lung cancer less
han or equal to 2 cm in diameter (stage IA) was 96.7%
95% confidence index [CI] 7.5) for those who underwent
-VATS, 95.2% (95% CI, 8.0) for those who underwent
-VATS, and 97.2% (95% CI, 8.7) for those who under-
ent open surgery. However, there was no statistical
ifference between survivals when comparing the 3
roups (Figure 6).
igure 5. Kaplan-Meier survival curve showing the overall sur-
ivals after surgery for stage IA non–small cell lung cancer.
auses of death included brain metastasis (n  1), other cancers
igure 4. Length of hospitalization. Values are mean  standard
eviation. c-VATS, Complete VATS; a-VATS, assisted VATS.n  2), and different disease (n  1).
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TSiscussion
here is now a growing body of evidence to suggest that the
ody’s immune function is better preserved after VATS
han after thoracotomy, as documented by decreased cyto-
ine release and activated lymphocyte function.9-11 Since
mmunosurveillance is believed to be important, surgically
nduced immunosuppression may predispose to increased
umor growth and recurrence. It is widely recognized that
ost cases of lung cancer recurrence arise at sites distant
rom the primary tumor site, and most cancers that recur are
ikely to be metastatic at initial exploration.9 Taken to-
ether, these findings seem to support the use of the VATS
pproach for lung cancer in terms of preserving host immu-
ity and optimizing long-term survival. Inasmuch as major
esection for early lung cancer is a common operation (one
f the most common for a general thoracic surgeon), even a
light advantage of one technique over another could have
ar-reaching implications. However, there is a notable lack
f data in the published literature regarding long-term sur-
ival after VATS lobectomy, which has limited the wide-
pread use of this technique.12 The present study evaluated
ong-term outcome data in patients with early lung cancer
fter the use of various lobectomy techniques and conven-
ional thoracotomy in different institutions, whereas out-
omes after VATS lobectomy in past reports have been
igure 6. Kaplan-Meier survival curves for patients with clinical
tage IA disease who underwent lobectomy under complete
ATS (c-VATS), assisted VATS (a-VATS), or open conventional
ABLE 3. Recurrent diseases
Local recurrence
-VATS (50 cases) No B
B
-VATS (31 cases) No B
pen (55 cases) Local recurrence, 1 case; alive Lidhoracotomy.
The Journal of Thoracicompared with historical controls from other studies.12,13
his trial could be performed because all attending institu-
ions own the common programs for operative indication,
reoperative and postoperative schedule, and training their
egistrars for the patients with lung cancer.
To assess the postoperative recovery status, we applied
he method of measuring the changes of the acceleration in
hysical activity with the ACT for the patients who under-
ent thoracic surgery for the first time, successfully dem-
nstrating the differences among a variety of VATS lobec-
omy and conventional approaches. It has been difficult to
ompare the benefits of purely endoscopic approaches to the
ther approaches regarding the postoperative recovery sta-
us, because a variety of factors may affect these results,
uch as pain, drainage period, and the response in cytokine
nd endocrine related to the invasiveness of the procedure.8
owever, the ACT appears to be useful for quantitatively
xpressing those benefits. The better results in the early
ostoperative period of c-VATS as compared with a-VATS
nd conventional thoracotomy, including less intraoperative
leeding, faster recovery, and shorter hospitalization, may be
ttributed to minimization of immune disturbance and preser-
ation of host immunity at the time of resection. These data
ay support the use of complete endoscopic surgery for pa-
ients with stage IA lung cancer, although more evidence
hould be accumulated to clarify those contributions.7
In the past several years, there have been tremendous
dvancements in the field of adjuvant chemotherapy for
atients with lung cancer, and this therapeutic modality is
xpected to play an increasing role in optimizing out-
omes.14,15 Since chemotherapy produces better outcomes
n patients with better functional status, the use of surgical
echniques that preserve near-term functional status (eg,
-VATS) may allow earlier institution of adjuvant chemo-
herapy and ultimately result in even better outcomes. Al-
hough this study was conducted in patients with stage IA
ung cancer, c-VATS may also be of use in advanced cases
hat require adjuvant chemotherapy.
This study design was limited to retrospective investiga-
ion, and a prospective randomized controlled study on a
arger scale is required to reach definitive conclusions re-
arding the efficacy of c-VATS relative to other tech-
iques.12 In our experience, the 5-year survival of patients
ith peripheral NSCLC less than or equal to 2 cm in
Metastasis Other disease
metastasis, 1 case; dead Pancreatic cancer, 1 case; dead
etastasis, 1 case; dead
etastasis, 1 case; alive Colon cancer, 1 case; dead
etastasis, 1 case; alive Pneumonia, 1 case; deadrain
one m
one miameter (stage IA) was 96.7% after c-VATS, 95.2% after
and Cardiovascular Surgery ● Volume 132, Number 3 511
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G
TS-VATS, and 97.2% after open surgery, revealing that
ong-term survival was comparable among 3 different ap-
roaches. The improved long-term survival seen in the
resent study relative to previous studies may be related to
election bias of patients with better prognostic factors, such
s a larger number of female patients, adenocarcinomas, or
ronchioloalveolar carcinomas. Recently, a growing body
f evidence has shown that patients with a tumor of 2 cm or
ess in diameter have a better survival than those with a
umor of 2.1 to 3.0 cm in diameter and that smaller tumor
ize at diagnosis is associated with improved curability
ithin stage IA NSCLCs, which we speculate is one of the
easons for the better survivals in our study.16-18 In addition,
he better outcomes may be further exaggerated by the
imited number of patients available.12,19 Therefore, com-
arisons between the present data and previous studies
hould be performed with caution and only in the context of
ecognizing differences in patient characteristics. Regard-
ess, this use of a retrospective multi-institutional comparison
ith common surgical programs yields higher-order data than
imple comparison of outcomes reported by different insti-
utions without standardized protocols. We appreciate that
sing the retrospective format may not be the ideal ap-
roach, but we think that it is a fair way to combine the data
rom three affiliated institutions and to assess the results
rom a larger combined population.
In conclusion, these data suggest that in experienced
ands, VATS lobectomy is a safe procedure that may go
ell beyond the early postoperative period. Further, more
mportantly, VATS lobectomy can be regarded as an ac-
eptable cancer operation for patients with peripheral
SCLC less than or equal to 2 cm in diameter (clinical stage
A) with the same long-term survivals as open surgery.
We thank Professor Anthony P. C. Yim and Dr Alan D. L.
ihoe for their invaluable opinions and encouragement in the
ompletion of this study. The authors also thank Ms Naoko Araki
or her excellent and heartfelt assistance in the preparation of this
anuscript.
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